MUC1 Activated T Cells
Adoptive Transfer of MUC1 Activated T Cells for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma
What's the purpose of the trial?
This phase I trial tests the safety, side effects and best dose of MUC1-activated T cells in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory) and is positive for expression of the MUC1 protein.
Trial status
Active, Not Recruiting
Phase
Phase 1
Enrollment
5
Last Updated
1 month ago
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.